scispace - formally typeset
R

Robert John Steffan

Researcher at Princeton University

Publications -  63
Citations -  2058

Robert John Steffan is an academic researcher from Princeton University. The author has contributed to research in topics: Alkyl & Transplantation. The author has an hindex of 25, co-authored 63 publications receiving 2005 citations.

Papers
More filters
Patent

Silyl ethers of rapamycin

TL;DR: In this article, a method of using rapamycin 42-[O-[(1, 1-dimethylethyl)-dimethylsilyl] ether for the preparation of 31-substituted Rapamycin derivatives was presented.
Journal ArticleDOI

Identification of pathway-selective estrogen receptor ligands that inhibit NF-κB transcriptional activity

TL;DR: This pathway-selective ligand does not promote the classic actions of estrogens such as stimulation of uterine proliferation or ER-mediated gene expression, but is a potent antiinflammatory agent, as demonstrated in the HLA-B27 transgenic rat model of inflammatory bowel disease.
Patent

Rapamycin 42-sulfonates and 42-(N-Carboalkoxy)Sulfamates Useful as Immunosuppressive Agents

TL;DR: A rapamycin derivative is a derivative of Rapamycin of general formula (I) where R1 is alkyl, alkenyl, or alkynyl containing 1 to 6 carbon atoms; or an aromatic moiety selected from the group consisting of phenyl and naphthyl or a heterocyclic moiety selecting from the groups consisting of thiophenyl and quinolinyl or NHCO2 R2 wherein R2 is lower alkyls containing 1-6 carbon atoms or a pharmaceutically acceptable salt thereof.
Patent

Carboxylic acid esters of rapamycin

TL;DR: A compound of structure (I) is defined as a compound of which the substituent is selected from alkyl, aralkyl, fluorenylmethyl, or phenyl which is optionally mono-, di-, or tri-substituted.
Journal ArticleDOI

LXR ligand lowers LDL cholesterol in primates, is lipid neutral in hamster, and reduces atherosclerosis in mouse.

TL;DR: Way-252623 (LXR-623) is a highly selective and orally bioavailable synthetic modulator of LXR, which demonstrated efficacy for reducing lesion progression in the murine LDLR−/− atherosclerosis model with no associated increase in hepatic lipogenesis either in this model or Syrian hamsters.